128 institutions hold shares in Evofem Biosciences Inc. (EVFM), with 2.1M shares held by insiders accounting for 2.53% while institutional investors hold 34.86% of the company’s shares. The shares outstanding are 81.32M, and float is at 78.84M with Short Float at 11.33%. Institutions hold 33.98% of the Float.
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The top institutional shareholder in the company is Invesco Ltd. with over 12.7 million shares valued at $30.61 million. The investor’s holdings represent 15.28% of the EVFM Shares outstanding. As of Dec 30, 2020, the second largest holder is Blackrock Inc. with 5.21 million shares valued at $12.56 million to account for 6.27% of the shares outstanding. The other top investors are Vanguard Group, Inc. (The) which holds 3.6 million shares representing 4.33% and valued at over $8.67 million, while Heartland Advisors Inc. holds 3.09% of the shares totaling 2.57 million with a market value of $6.2 million.
Evofem Biosciences Inc. (NASDAQ: EVFM) is -27.80% lower on its value in year-to-date trading and has touched a low of $1.65 and a high of $6.87 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The EVFM stock was last observed hovering at around $1.82 in the last trading session, with the day’s loss setting it -0.08% off its average median price target of $6.00 for the next 12 months. It is also 75.14% off the consensus price target high of $7.00 offered by 4 analysts, but current levels are 42.0% higher than the price target low of $3.00 for the same period.
Currently trading at $1.74, the stock is -25.55% and -43.28% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.24 million and changing -4.40% at the moment leaves the stock -37.09% off its SMA200. EVFM registered -66.54% loss for a year compared to 6-month loss of -35.79%. The firm has a 50-day simple moving average (SMA 50) of $3.0624 and a 200-day simple moving average (SMA200) of $2.6792.
The stock witnessed a -21.27% gain in the last 1 month and extending the period to 3 months gives it a -29.27%, and is 0.58% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.22% over the week and 8.55% over the month.
Evofem Biosciences Inc. (EVFM) has around 147 employees, a market worth around $148.51M and $0.40M in sales. Distance from 52-week low is 5.45% and -74.67% from its 52-week high. The company has generated returns on investments over the last 12 months (-131.30%).
Evofem Biosciences Inc. (EVFM) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Evofem Biosciences Inc. (EVFM) is a “Overweight”. 4 analysts offering their recommendations for the stock have an average rating of 2.00, where 1 rate it as a Hold and 0 think it is a “Overweight”. 3 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Evofem Biosciences Inc. is expected to release its quarterly report on 08/10/2021 and quarterly earnings per share for the current quarter are estimated at -$0.49 with sales reaching $1.63M over the same period.The EPS is expected to shrink by -6.50% this year, but quarterly earnings will post 5,287.90% year-over-year.
Evofem Biosciences Inc. (EVFM) Insider Activity
A total of 8 insider transactions have happened at Evofem Biosciences Inc. (EVFM) in the last six months, with sales accounting for 0 and purchases happening 8 times. The most recent transaction is an insider purchase by PELLETIER SAUNDRA L, the company’s Chief Executive Officer. SEC filings show that PELLETIER SAUNDRA L bought 45,249 shares of the company’s common stock on Mar 09 at a price of $2.28 per share for a total of $0.1 million. Following the purchase, the insider now owns 0.91 million shares.
Evofem Biosciences Inc. disclosed in a document filed with the SEC on Nov 17 that File Justin J. (Chief Financial Officer) bought a total of 7,760 shares of the company’s common stock. The trade occurred on Nov 17 and was made at $2.17 per share for $16839.0. Following the transaction, the insider now directly holds 0.26 million shares of the EVFM stock.
Still, SEC filings show that on Nov 17, Fitzpatrick Alexander A (General Counsel and Secretary) acquired 9,090 shares at an average price of $2.20 for $19998.0. The insider now directly holds 143,542 shares of Evofem Biosciences Inc. (EVFM).